AI Score

Unlock

Theravance Biopharma Inc. (TBPH)

AI Score

Unlock

9.15

-0.20 (-2.14%)

At close: Mar 03, 2025, 3:59 PM

9.15

0.00%

After-hours: Mar 03, 2025, 04:00 PM EST

No 1D chart data available

Bid	8.92
Market Cap	449.94M
Revenue (ttm)	63.37M
Net Income (ttm)	-49.54M
EPS (ttm)	-1.15
PE Ratio (ttm)	-7.96
Forward PE	10.05
Analyst	Hold

Ask	9.6
Volume	218,679
Avg. Volume (20D)	219,491
Open	9.31
Previous Close	9.35
Day's Range	9.12 - 9.38
52-Week Range	7.44 - 10.90
Beta	0.15

About TBPH

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical tr...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 16, 2014

Employees 99

Stock Exchange NASDAQ

Ticker Symbol TBPH

Website https://www.theravance.com

Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for TBPH stock is "Hold." The 12-month stock price forecast is $12.5, which is an increase of 36.61% from the latest price.

Buy 50.00%

Hold 50.00%

Sell 0.00%

Stock Forecasts

Earnings Surprise

Theravance Biopharma has released their quartely earnings on Feb 26, 2025:

Revenue of $18.75M exceeds estimates by $1.66M, with 6.77% YoY growth.

EPS of -0.05 exceeds estimates by 0.03, with 70.59% YoY growth.

Why Price Moved

3 months ago

+8.64%

Theravance Biopharma shares are trading higher aft... Unlock content with Pro Subscription

6 months ago

-18.35%

Theravance Biopharma shares are trading lower after the company reported mixed Q2 financial results. Also, Leerink Partners downgraded the stock from Outperform to Market Perform and lowered its price target from $15 to $10.

News

4 days ago · zacks.com

Theravance's Q4 Loss In Line With Estimates, Sales Beat

TBPH's fourth-quarter earnings match estimates while sales beat the same marginally. Increased collaboration revenues from Viatris drive revenues higher.

5 days ago · seekingalpha.com

Theravance Biopharma, Inc. (TBPH) Q4 2024 Earnings Call Transcript

Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants Rick Winningham – Chief Executive Officer Rhonda Farnum – Chief Business Of...

6 days ago · zacks.com

Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates

Theravance Biopharma (TBPH) came out with a quarterly loss of $0.05 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.03 per share a year ago.

1 month ago · zacks.com

Theravance Bio (TBPH) Soars 8.3%: Is Further Upside Left in the Stock?

Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incre...

2 months ago · zacks.com

Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?